



## Development of Novel Radiotracers for PET Imaging

Guest Editors:

**Prof. Dr. Jonathan Bayldon  
Baell**

School of Pharmaceutical  
Sciences, Nanjing Tech  
University, No. 30 South Puzhu  
Road, Nanjing 211816, China

**Dr. Ramesh Mudududdla**

School of Pharmacy, University of  
Wisconsin-Madison, Madison, WI,  
USA

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editors

PET (positron emission tomography) is a medical imaging technique that uses a radioactive tracer to visualize metabolic and physiological processes in the body. This can help researchers better understand the mechanisms of disease and develop new therapies. The development of new radiotracers involves a multidisciplinary approach that combines chemistry, biology, pharmacology, and imaging sciences. Additionally, the radiotracer should have a high selectivity and affinity for the target molecule or biological process of interest while also minimizing off-target binding and nonspecific uptake. There are several approaches to developing new radiotracers, including the use of small molecules, peptides, antibodies, and nanoparticles. Overall, the development of novel radiotracers for PET imaging is a challenging yet critical area of research with tremendous potential for advancing our understanding of various biological processes and improving the diagnosis and treatment of diseases. This Special Issue aims to focus on the state of the art in the field of cancer and other neurological applications.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)